Indications for Desmopressin in the Treatment of Bleeding Disorders
| . | . | Grading of Recommendation . | Level of Evidence . |
|---|---|---|---|
| Established | Mild hemophilia A | B | III |
| vWD (see Table 2) | B | III | |
| Possible | Congenital defects of platelet function | C | IV |
| Uremia | C | IV | |
| Liver cirrhosis | C | IV | |
| Drug-induced bleeding (heparin, hirudin, antiplatelet agents, dextran, streptokinase) | C | IV | |
| Doubtful | Cardiac surgery | A | I |
| General surgery | A | I |
| . | . | Grading of Recommendation . | Level of Evidence . |
|---|---|---|---|
| Established | Mild hemophilia A | B | III |
| vWD (see Table 2) | B | III | |
| Possible | Congenital defects of platelet function | C | IV |
| Uremia | C | IV | |
| Liver cirrhosis | C | IV | |
| Drug-induced bleeding (heparin, hirudin, antiplatelet agents, dextran, streptokinase) | C | IV | |
| Doubtful | Cardiac surgery | A | I |
| General surgery | A | I |
“Established” indications are those in which the hemostatic efficacy of desmopressin has been demonstrated clinically; “Possible” indications, those in which clinical data are too preliminary or inconclusive; “Doubtful” indications, those in which desmopressin is not efficacious clinically. Grading of recommendations and levels of evidence are those proposed by the Agency for Health Care Policy and Research Publications of the US Department of Health and Human Services.